Alnylam Pharmaceuticals
NEWS
It was a busy week for clinical trial announcements. Here’s a look.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
Data shows the long-term efficacy and tolerability as well as the continued ability of Onpattro to reverse or halt neuropathy progression.
Cambridge, Mass.-based Alnylam Pharmaceuticals indicated that its ENVISION Phase III trial of givosiran was positive for acute hepatic porphyria (AHP).
Under the terms of the agreement, Regeneron is paying $400 million upfront to Alnylam and acquiring another $400 million in equity at a price per share of $90, or 4.44 million common shares.
Despite releasing positive data on its Phase III ENVISION trial, Alnylam stock dropped 7.5 percent. Although not completely clear why, the drop may be related to a high percentage of serious adverse events observed in the trial.
For its 2019 list of the top 50 most innovative companies, Fast Company selected 10 from the biotech industry that are having a significant impact on the treatment of patients. The first five are highlighted.
JOBS
IN THE PRESS